Home / Stocks / Aarey Drugs & Pharm Ltd
AAREYDRUGS

Aarey Drugs & Pharm Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹101.57

Change

+1.31 (1.31%)

Open

₹98.5

Prev. Close

₹100.26

Day High

₹102.01

Day Low

₹98.02

Volume Analysis

Traded

112,885

Delivered

77,345

Delivery %

68.52%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹107.03 ₹104.52 ₹103.04 ₹100.53 ₹99.05 ₹96.54 ₹95.06
Fibonacci ₹104.52 ₹103.0 ₹102.05 ₹100.53 ₹99.01 ₹98.06 ₹96.54
Camarilla ₹102.67 ₹102.3 ₹101.94 ₹100.53 ₹101.2 ₹100.84 ₹100.47

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+50.36%

1 Week

-0.78%

1 Month

+14.11%

3 Months

+12.66%

6 Months

+90.63%

1 Year

+29.34%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Company Overview

Sector

Healthcare

Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.

TopFund Analysis

Aarey Drugs & Pharm Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 53/100. The strongest factor is Corporate Governance (65/100), while Risk & Volatility (36/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling. FII holding has been rising.

TopFund Score — Fundamentals Quality

53/100 — Average

Data confidence: 60/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Corporate Governance

65

Institutional Ownership

54

Risk & Volatility

36

Liquidity

50

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Trading window closed from October 1, 2026 until 48 hours after Q2 FY2026 results.

36th AGM scheduled for 30 September 2026; annual report link shared with unregistered email shareholders.

36th AGM on 30 September 2026 via VC/OAVM; annual report circulated with related party approvals sought.

36th AGM on 30 September 2026 via VC/OAVM; annual report circulated, with related party transaction approvals.

Source: BSE regulatory filings, via Screener.in.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 50.04% → 42.79%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Aug 2026
Public 46.12% 51.31% 51.32% 51.81% 52.86% 52.86% 53.23% 54.07% 57.09% 56.49% 55.87% 51.31%
Promoters 50.04% 45.28% 45.28% 45.44% 44.8% 44.8% 44.8% 44.8% 39.05% 37.71% 37.71% 42.79%
FII 3.83% 3.4% 3.4% 2.75% 2.34% 2.34% 1.97% 1.13% 3.86% 4.18% 4.81% 4.41%
DII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.62% 1.62% 1.49%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Aarey Drugs & Pharm Ltd (this stock) — — — —
Sun Pharmaceutical Ind L 444,405 35.2 5.32 16.0%
Divi S Laboratories Ltd 255,487 85.8 15.25 16.5%
Torrent Pharmaceuticals L 189,746 85.0 20.11 27.4%
Apollo Hospitals Enter. L 128,055 60.9 13.51 21.2%
Zydus Lifesciences Ltd 115,890 23.8 4.32 21.2%
Cipla Ltd 111,060 31.0 3.23 11.6%

Which Mutual Funds Hold Aarey Drugs & Pharm Ltd?

Frequently Asked Questions about Aarey Drugs & Pharm Ltd

Community Sentiment

What are other investors saying about Aarey Drugs & Pharm Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.